Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants.

This review and analysis utilized whole-exome data from 469,391 UK Biobank participants to investigate the distribution and implications of TP53 variants. The study aimed to distinguish between germline and somatic clonal expansions and evaluate their association with cancer risk, including haematological malignancies and solid tumours. Secondary outcomes included variant allele fraction, haplotype-sharing analysis, disease penetrance, and missense variant pathogenicity.

The analysis revealed that germline variants were concentrated at sites linked to partial loss of p53 function and demonstrated lower disease penetrance. In contrast, classic Li-Fraumeni syndrome alleles appeared almost entirely somatic within the blood samples. The prevalence of somatic clonal expansion correlated with the pathogenicity of missense variants, suggesting a link between clonal expansion and variant nature.

Carriers with high variant allele fractions of classic Li-Fraumeni syndrome alleles conferred a markedly increased risk of haematological malignancy. However, this increased risk was not observed for solid tumours in this population. The study did not report specific adverse events, discontinuations, or tolerability data, as this was a genomic analysis rather than a clinical trial. No funding conflicts or limitations were reported in the provided data.

The practice relevance of this work lies in providing a scalable framework for variant classification in large-scale population genomics. Clinicians should note that the observational nature of the study limits causal inferences. The findings suggest that variant classification in large cohorts may need to account for the distinction between germline and somatic origins to accurately assess cancer risk.